Objective: To identify patterns of self-reported health problems relating to dose and duration of GC intake in unselected patients with rheumatoid arthritis from routine practice.
Methods: We analyzed data from 1,066 patients. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing GC treatment for >6 months and current doses of <5, 5-7.5 and >7.5 mg/d prednisone equivalent were compared to a group without any GC treatment for at least 12 months.
Results: The frequency of self-reported health problems was lowest in the group without GC exposition and increased with dosage. We observed two distinct dose-related patterns of adverse events: A “linear” rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath, and sleep disturbance. A “threshold pattern” describing an elevated frequency of events beyond a certain threshold value was observed at dosages of >7.5mg/d for glaucoma, depression/ listlessness and increase of blood pressure. Dosages of 5 mg/d or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/d).
Conclusion: The associations found are in agreement with biologic mechanisms and clinical observations. Since there is a paucity of real-life data on adverse effects of GCs prescribed to unselected groups of patients, our data may help the clinician to adapt therapy with GC accordingly and improve the benefit-risk-ratio.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.